Literature DB >> 20540849

[Effect of UGTIA6 A541G genetic polymorphism on the metabolism of valproic acid in Han epileptic children from Henan].

Yan Wang1, Li Gao, Yan-Ping Liu, Nan-Nan Huang, Shu-Jing Xu, Dong-Ju Ma.   

Abstract

OBJECTIVE: To investigate the distribution and frequency of UGTIA6 A541G genetic polymorphism in Han epileptic children from Henan and to evaluate the effect of UGTIA6 A541G genetic polymorphism on serum concentrations of valproic acid.
METHODS: The method of gas chromatography was used to assay serum concentrations of valproic acid. UGTIA6 A541G genetic polymorphism was screened by PCR-RFLP. Direct sequencing was used to confirm the expected sequences of each genotype.
RESULTS: The genotypic frequencies of UGTIA6 A541G were as follows: AA in 76 cases, AG in 65 cases and GG in 6 cases. The mean values of serum concentrations of valproic acid in patients with A541G AA, AG and GG were 3.91+/-1.57, 3.59+/-1.39 and 3.73+/-1.28 microg/mL, respectively (dose-adjusted trough concentration on a mg/kg basis). There were no significant differences in serum concentrations of valproic acid among the three groups.
CONCLUSIONS: UGT1A6 A541G gene polymorphism does not influence serum concentrations of valproic acid in Han epileptic children. Individual differences in serum concentrations of valproic acid may be attributed to many factors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20540849

Source DB:  PubMed          Journal:  Zhongguo Dang Dai Er Ke Za Zhi        ISSN: 1008-8830


  5 in total

1.  The effect of uridine diphosphate glucuronosyltransferase (UGT)1A6 genetic polymorphism on valproic acid pharmacokinetics in Indian patients with epilepsy: a pharmacogenetic approach.

Authors:  Murali Munisamy; Manjari Tripathi; Madhuri Behari; S Raghavan; D C Jain; Barghavi Ramanujam; Karthik Arumugam; Thiyagu Rajakannan; Surulivel Rajan Mallayasamy; Vivekanandhan Subbiah
Journal:  Mol Diagn Ther       Date:  2013-10       Impact factor: 4.074

Review 2.  Pharmacogenomics and histone deacetylase inhibitors.

Authors:  Andrew Kl Goey; Tristan M Sissung; Cody J Peer; William D Figg
Journal:  Pharmacogenomics       Date:  2016-10-21       Impact factor: 2.533

3.  UGT1A6 and UGT2B7 Gene Polymorphism and its Effect in Pediatric Epileptic Patients on Sodium Valproate Monotherapy.

Authors:  P B Nandith; Usha Adiga; Vijaya Shenoy; Sachidananda Adiga M N
Journal:  Indian J Pediatr       Date:  2021-01-05       Impact factor: 1.967

Review 4.  Effects of genetic polymorphism of drug-metabolizing enzymes on the plasma concentrations of antiepileptic drugs in Chinese population.

Authors:  Weixuan Zhao; Hongmei Meng
Journal:  Bioengineered       Date:  2022-03       Impact factor: 6.832

5.  Association of UGT1A6 gene polymorphism with clinical outcome in pediatric epileptic patients on sodium valproate monotherapy.

Authors:  N Banawalikar; S Adiga; U Adiga; V Shenoy; S Kumari; P Shetty; S Shetty; K P Sharmila
Journal:  Braz J Med Biol Res       Date:  2021-06-14       Impact factor: 2.590

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.